176 related articles for article (PubMed ID: 12199790)
1. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
Lee JH; Lee KH; Lee JH; Kim S; Seol M; Park CJ; Chi HS; Kang W; Kim ST; Kim WK; Lee JS
Br J Haematol; 2002 Sep; 118(4):1087-94. PubMed ID: 12199790
[TBL] [Abstract][Full Text] [Related]
2. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
[TBL] [Abstract][Full Text] [Related]
3. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
4. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation.
Salat C; Holler E; Kolb HJ; Pihusch R; Reinhardt B; Penovici M; Ledderose G; Hiller E
Leuk Lymphoma; 1999 Mar; 33(1-2):25-32. PubMed ID: 10194118
[TBL] [Abstract][Full Text] [Related]
5. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.
Salat C; Holler E; Kolb HJ; Reinhardt B; Pihusch R; Wilmanns W; Hiller E
Blood; 1997 Mar; 89(6):2184-8. PubMed ID: 9058743
[TBL] [Abstract][Full Text] [Related]
7. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients.
Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Hiller E; Andreesen R; Kolb HJ; Holler E; Pihusch R
Transplantation; 2005 Nov; 80(10):1376-82. PubMed ID: 16340778
[TBL] [Abstract][Full Text] [Related]
9. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
[TBL] [Abstract][Full Text] [Related]
10. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen.
Brodsky R; Topolsky D; Crilley P; Bulova S; Brodsky I
Am J Clin Oncol; 1990 Jun; 13(3):221-5. PubMed ID: 2346127
[TBL] [Abstract][Full Text] [Related]
11. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population.
Sartori MT; Spiezia L; Cesaro S; Messina C; Paris M; Pillon M; Saggiorato G; Pagnan A; Girolami A; Zanesco L; Cella G
Thromb Haemost; 2005 Apr; 93(4):682-9. PubMed ID: 15841312
[TBL] [Abstract][Full Text] [Related]
12. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
13. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
14. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
[TBL] [Abstract][Full Text] [Related]
15. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator.
Litzow MR; Repoussis PD; Schroeder G; Schembri-Wismayer D; Batts KP; Anderson PM; Arndt CA; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Noël P; Solberg LA; Letendre L; Hoagland HC
Leuk Lymphoma; 2002 Nov; 43(11):2099-107. PubMed ID: 12533034
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.
Carreras E; Bertz H; Arcese W; Vernant JP; Tomás JF; Hagglund H; Bandini G; Esperou H; Russell J; de la Rubia J; Di Girolamo G; Demuynck H; Hartmann O; Clausen J; Ruutu T; Leblond V; Iriondo A; Bosi A; Ben-Bassat I; Koza V; Gratwohl A; Apperley JF
Blood; 1998 Nov; 92(10):3599-604. PubMed ID: 9808553
[TBL] [Abstract][Full Text] [Related]
17. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.
McDonald GB; Hinds MS; Fisher LD; Schoch HG; Wolford JL; Banaji M; Hardin BJ; Shulman HM; Clift RA
Ann Intern Med; 1993 Feb; 118(4):255-67. PubMed ID: 8420443
[TBL] [Abstract][Full Text] [Related]
18. Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide.
Lund MB; Brinch L; Kongerud J; Boe J
Eur Respir J; 2004 Jun; 23(6):901-5. PubMed ID: 15219005
[TBL] [Abstract][Full Text] [Related]
19. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
[TBL] [Abstract][Full Text] [Related]
20. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
